Cabenuva/Apretude Enrollment Form



Fax Referral To: 1-855-297-1270

Phone: 1-888-280-1190 Address: 280 Avenida Jesus T. Pinero Ste B Rio , PR 00927 NCPDP: 4026325

	imple Steps to Submitt	ing a Referral	
PATIENT INFORMATION (Patient mu	ust complete highlighted area)	Scheduled Inject	tion Date:
Patient Name:City, State, ZIP Code: Al	Address:		
City, State, ZIP Code:	DOB:	Last Four of SSN:	Gender: 🔲 Male 🔲 Female
Primary Phone:Al	Iternate Phone:	Email:	
By providing the phone number(s) and email address above prescription(s), account and health care. Standard data rate Note: Carrier charges may apply. By providing the phone nu from CVS Specialty® about your prescription(s), account, an Specialty Pharmacy will attempt to contact by phone.	e, you are consenting to receive autom es apply. Message frequency varies. imber(s) and email address above, you	ated calls, emails and/or text are consenting to receive aut	messages from CVS Specialty* about your comated calls, emails and/or text messages
Designated Patient Contact			
By signing below, I authorize my Contact, liste ncluding ability to make decisions on my beha extended-release injectable suspension) or Ap- iable for any decision(s) made by the Contact Contact as set forth above:	alf, for which I will remain liabl oretude (cabotegravir extende	e, regarding delivery of ed-release injectable su	Cabenuva (cabotegravir/rilpiviring spension). CVS Specialty is not
Contact Name:	Relatio	nship:	Phone:
Patient's Signature:			
Patient Authorization			
my Cabenuva or Apretude prescription medica scheduled appointment. I understand that my will not outreach/contact me and/or my desig circumstances.** I further agree to pay to CVS without prior outreach to me or my designated	signature below serves as the nated contact on this form, pr Specialty any required copay	e Patient Ship Authorization to shipping medica	ation, which means the pharmacy tion except in certain
Patient's Authorization: *CVS Specialty may contact patient and/or patient's designated and secondaries and Medicaid patients because gove required to pay for a prescription in accordance with a Plan, palance, if any, paid by a Plan.	rnment payors are excluded from this	offering. Copayment, copay o	r coinsurance means the amount a member i
PRESCRIBER INFORMATION			
- Facility Type: 🗌 Private Practice 🗌 Outpa	atient Hospital/Clinic 🗌 Otl	ner:	
Prescriber's First Name:			
State License#:DEA	#·	Practice/Facility	v Name:
Practice Address (Ship to Address):			
State/ZIP Code:			
			number:
	Contact's Ph		
INSURANCE INFORMATION (Please			
s the Patient Insured? \square Yes \square No \square Is the F			
Policy Holder's Name:	Policy Holder's	DOB:Re	elationship to Patient:
Medical Insurance:			
Prescription Insurance:0		Prescription Plan Telep	hone:
	Group #:	_ RX BIN #:	RX PCN #:
Check box if patient is enrolled in manuface DIAGNOSIS AND CLINICAL INFORM			
		• • • • • • • • • • • • • • • • • • • •	
	Diagnosis (IOD		
B20 Human Immunodeficiency Virus (HIV)			V pre-exposure prophylaxis
B20 Human Immunodeficiency Virus (HIV) Other Code: Description			V pre-exposure prophylaxis
B20 Human Immunodeficiency Virus (HIV)			V pre-exposure prophylaxis ☐ kg Height: ☐ in ☐ cn
B20 Human Immunodeficiency Virus (HIV) Other Code: Description Patient Clinical Information: Allergies:	☐ NKDA Wei☐ Yes ☐ No	ght: 🗆 lb [☐ kg Height: ☐ in ☐ cr

atient Name:	ease Complete Patient, Preso Patie	ent DOB:	na Patient Ctime	Patient Phone:	
rescriber Name:	Patient DOB:				
reatment status: New 1	to therapy \square Continuation of thera	py: Date	of last treatment	/	
PRESCRIPTION INFO	ORMATION (to be completed by	prescrib	er only)		
MEDICATION	STRENGTH		DOSE & DIREC	TIONS	QUANTITY/REFILLS
Apretude	1				•
Apretude 600 mg	600 mg/3mL single-dose vial of cabotegravir	☐ Loading dose (Month 1 & Month 2): Inject 3 mL into the muscle at month 1 and month 2, then every 2 months thereafter		Quantity: 1 dosing kit Refills: 1	
Apretude 600 mg Injection Kit	600 mg/3mL single-dose vial of cabotegravir	☐ Maintenance dose (Month 4+): Inject 3 mL into the muscle every 2 months		Quantity: 1 dosing kit Refills:	
Cabenuva					
Option 1: Every-2-Month [Dosing		-		
Cabenuva 600/900 mg Injection Kit	☐ 600 mg/3 mL single-dose vial of cabotegravir + 900 mg/3 mL single-dose vial of rilpivirine	☐ Loading dose (Month 1 & Month 2): Inject 3 mL of cabotegravir and 3 mL of rilpivirine into the muscle once monthly for 2 months then maintenance dose as directed		Quantity: 1 dosing kit Refills: <u>1</u>	
☐ Cabenuva 600/900 mg Injection Kit	600 mg/3 mL single-dose vial of cabotegravir + 900 mg/3 mL single-dose vial of rilpivirine	☐ Maintenance dose (Month 4+): Inject 3 mL of cabotegravir and 3 mL of rilpivirine into the muscle every 2 months		Quantity: 1 dosing kit Refills:	
Option 2: Every-1-Month [Dosing				
☐ Cabenuva 600/900 mg Injection Kit	600 mg/3 mL single-dose vial of cabotegravir + 900 mg/3 mL single-dose vial of rilpivirine	Loading dose: Inject 3 mL of cabotegravir and 3 mL of rilpivirine into the muscle on day 1. Follow with maintenance dose in 1 month		Quantity: 1 dosing kit Refills: <u>None</u>	
Cabenuva 400/600 mg	400 mg/2 mL single-dose vial of cabotegravir + 600 mg/2 mL single-dose vial of rilpivirine	☐ Maintenance dose: Inject 2 mL of cabotegravir and 2 mL of rilpivirine into the muscle every month		Quantity: 1 dosing kit Refills:	
-	ATURE REQUIRED (STAMP	1	TURE NOT ALLO		
DAW / May Not Substitute		Substitution Permissible		D	
Prescriber's Signature:_	Date:		Prescriber's Signa	ature:	Date:

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or one of its affiliates.